Moreover, adding MEKi to ICI could limit immune-related resistance mechanisms, i.e., BRAFi-resistant melanoma cells had increased PD-L1 expression that could be reversed by MEKi addition [13,17]. This evidence concerns the gene CD274 and melanoma.